Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
2019-nCoV, which is a novel coronavirus emerged in Wuhan, China, at the end of 2019, has caused at least infected 11,844 as of Feb 1, 2020. However, there is no specific antiviral treatment or vaccine currently. Very recently report had suggested that novel CoV would use the same cell entry receptor, ACE2, as the SARS-CoV. In this report, we generated a novel recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. An ACE2 mutant with low catalytic activity was also used in the study. The fusion proteins were then characterized. Both fusion proteins has high affinity binding to the receptor-binding domain (RBD) of SARS-CoV and 2019-nCoV and exerted desired pharmacological properties. Moreover, fusion proteins potently neutralized SARS-CoV and 2019-nCoV in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they could have potential applications for diagnosis, prophylaxis, and treatment of 2019-nCoV.
Article activity feed
-
SciScore for 10.1101/2020.02.01.929976: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources 293T cells transfected with the indicated CoV S glycoprotein genes were preincubated with different fusion proteins at room temperature for 15 min, then mixed with 293T cells transfected with ACE2 at 1:1 ratio and incubated at 37°C for 4 h. 293Tsuggested: NoneExperimental Models: Organisms/Strains Sentences Resources TIGIT-Ig, which were described in our pervious report13, served as a control in our study. report13suggested: NonePharmacokin… SciScore for 10.1101/2020.02.01.929976: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources 293T cells transfected with the indicated CoV S glycoprotein genes were preincubated with different fusion proteins at room temperature for 15 min, then mixed with 293T cells transfected with ACE2 at 1:1 ratio and incubated at 37°C for 4 h. 293Tsuggested: NoneExperimental Models: Organisms/Strains Sentences Resources TIGIT-Ig, which were described in our pervious report13, served as a control in our study. report13suggested: NonePharmacokinetics: We used BALB/c mice to determine the pharmacokinetic profile of the fusion protein. BALB/csuggested: RRID:IMSR_ORNL:BALB/cRl)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
-